Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Authors: Alex Tsodikov, Roman Gulati, Ruth Etzioni
Journal: Annals of Internal Medicine (2018)

Letters17 April 2018Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsAlex Tsodikov, PhD, Roman Gulati, MS, and Ruth Etzioni, PhDAlex Tsodikov, PhDUniversity of Michigan, Ann Arbor, Michigan (A.T.), Roman Gulati, MSFred Hutchinson Cancer Research Center, Seattle, Washington (R.G., R.E.), and Ruth Etzioni, PhDFred Hutchinson Cancer Research Center, Seattle, Washington (R.G., R.E.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0738 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the opportunity to clarify certain areas of confusion about our study of prostate cancer screening in the ERSPC and PLCO trials. Our MLT metric is a group-level measure reflecting the intensity of screening and diagnosis on each group of each trial. It aggregates group-specific screening frequencies, PSA thresholds, and biopsy adherence into 1 measure. Of note, we do not use the MLT to determine screening benefit or as a substitute for the definitive end point of screening as Drs. Prorok and Miller suggest. Rather, our survival analysis uses an established statistical framework: Cox regression on prostate ...Reference1. Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126:2387-93. [PMID: 19739124] doi:10.1002/ijc.24870 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Michigan, Ann Arbor, Michigan (A.T.)Fred Hutchinson Cancer Research Center, Seattle, Washington (R.G., R.E.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-2586. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Alex Tsodikov , Roman Gulati , Eveline A.M. Heijnsdijk , Paul F. Pinsky , Sue M. Moss , Sheng Qiu , Tiago M. de Carvalho , Jonas Hugosson , Christine D. Berg , Anssi Auvinen , Gerald L. Andriole , Monique J. Roobol , E. David Crawford , Vera Nelen , Maciej Kwiatkowski , Marco Zappa , Marcos Luján , Arnauld Villers , Eric J. Feuer , Harry J. de Koning , Angela B. Mariotto , and Ruth Etzioni Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Philippe Autier and Peter Boyle Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Join Y. Luh , Steven E. Finkelstein , Jeff M. Michalski , and Howard Sandler MD Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Shinkan Tokudome , Ryosuke Ando , and Shuji Hashimoto Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Stuart G. Baker Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Philip C. Prorok and Anthony B. Miller Metrics Cited byIntroduction to a seminar on revisiting the value of PSA-based prostate cancer screeningMicro-Ultrasound: a way to bring imaging for prostate cancer back to urologyProstate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998–2017Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate CancerAbrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendationpiR-19166 inhibits migration and metastasis through CTTN/MMPs pathway in prostate carcinomaECCO Essential Requirements for Quality Cancer Care: Prostate cancerUnifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer ManagementA blueprint for cancer screening and early detection: Advancing screening's contribution to cancer controlClinical Issues for Prostate-Specific Antigen Screening: A Narrative ReviewGegendarstellung zu: PSA‑ScreeningÉmergence de la simple surveillance du cancer de prostate et des traitements partiels. Rôle clé de l'IRM. 17 April 2018Volume 168, Issue 8Page: 608-609KeywordsBiopsyCancer detection and diagnosisCancer screeningDisclosureIntent to treat analysisMedical risk factorsMortalityProstate cancerStatistical modelsSurvival analysis ePublished: 17 April 2018 Issue Published: 17 April 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...